Michael Farrell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/961207/publications.pdf

Version: 2024-02-01

272 papers

17,719 citations

68 h-index 123 g-index

281 all docs

281 docs citations

times ranked

281

15984 citing authors

#	Article	IF	Citations
1	The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction, 2002, 97, 1183-1194.	3.3	1,344
2	Validation of the alcohol, smoking and substance involvement screening test (ASSIST). Addiction, 2008, 103, 1039-1047.	3.3	825
3	Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction, 2018, 113, 1905-1926.	3.3	685
4	Metaâ€analysis of drugâ€related deaths soon after release from prison. Addiction, 2010, 105, 1545-1554.	3.3	518
5	Prevalence and correlates of self-reported psychotic symptoms in the British population. British Journal of Psychiatry, 2004, 185, 298-305.	2.8	482
6	Psychosis, victimisation and childhood disadvantage. British Journal of Psychiatry, 2004, 185, 220-226.	2.8	478
7	The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction, 1998, 93, 1857-1867.	3.3	399
8	The National Psychiatric Morbidity Surveys of Great Britain – initial findings from the Household Survey. Psychological Medicine, 1997, 27, 775-789.	4.5	363
9	Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain, 2018, 159, 1932-1954.	4.2	321
10	The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. Psychological Medicine, 1998, 28, 9-19.	4.5	293
11	Obsessive-Compulsive Disorder: Prevalence, Comorbidity, Impact, and Help-Seeking in the British National Psychiatric Morbidity Survey of 2000. American Journal of Psychiatry, 2006, 163, 1978-1985.	7.2	281
12	Debt, income and mental disorder in the general population. Psychological Medicine, 2008, 38, 1485-1493.	4.5	277
13	Acute risk of drugâ€related death among newly released prisoners in England and Wales. Addiction, 2008, 103, 251-255.	3.3	255
14	Nicotine, alcohol and drug dependence and psychiatric comorbidity. British Journal of Psychiatry, 2001, 179, 432-437.	2.8	250
15	Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence. JAMA Psychiatry, 2021, 78, 979.	11.0	244
16	The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction, 2012, 107, 501-517.	3.3	215
17	Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Molecular Psychiatry, 2019, 24, 1868-1883.	7.9	215
18	CONCURRENT AND CONSTRUCT VALIDITY OF THE AUDIT IN AN URBAN BRAZILIAN SAMPLE. Alcohol and Alcoholism, 2005, 40, 584-589.	1.6	210

#	Article	IF	CITATIONS
19	Unequal access and unmet need: neurotic disorders and the use of primary care services. Psychological Medicine, 2000, 30, 1359-1367.	4.5	200
20	Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. Neuropsychopharmacology, 2017, 42, 1752-1765.	5.4	190
21	Global, regional, and countryâ€level estimates of hepatitis C infection among people who have recently injected drugs. Addiction, 2019, 114, 150-166.	3.3	178
22	Socioeconomic status, standard of living, and neurotic disorder. Lancet, The, 1998, 352, 605-609.	13.7	173
23	Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Health, The, 2018, 3, e341-e350.	10.0	172
24	Responding to global stimulant use: challenges and opportunities. Lancet, The, 2019, 394, 1652-1667.	13.7	169
25	Substance misuse and psychiatric comorbidity. Addictive Behaviors, 1998, 23, 909-918.	3.0	165
26	The impact of opioid substitution therapy on mortality postâ€release from prison: retrospective data linkage study. Addiction, 2014, 109, 1306-1317.	3.3	165
27	Psychiatric and social aspects of suicidal behaviour in prisons. Psychological Medicine, 2005, 35, 257-269.	4.5	160
28	Development of the treatment outcomes profile. Addiction, 2008, 103, 1450-1460.	3.3	158
29	Psychiatric symptoms among clients seeking treatment for drug dependence. British Journal of Psychiatry, 2000, 176, 285-289.	2.8	151
30	Pharmacological treatment of cocaine dependence: a systematic review. Addiction, 2002, 97, 931-949.	3.3	149
31	The role of <scp>C</scp> ochrane reviews in informing international guidelines: a case study of using the <scp>G</scp> rading of <scp>R</scp> ecommendations, <scp>A</scp> ssessment, <scp>D</scp> evelopment and <scp>E</scp> valuation system to develop World Health Organization guidelines for the psychosocially assisted pharmacological treatment of opioid dependence.	3.3	147
32	Addiction, 2015, 110, 891-898. The National Psychiatric Morbidity Surveys of Great Britain – strategy and methods. Psychological Medicine, 1997, 27, 765-774.	4.5	140
33	Neurotic disorders and the receipt of psychiatric treatment. Psychological Medicine, 2000, 30, 1369-1376.	4.5	140
34	Psychopathy among prisoners in England and Wales. International Journal of Law and Psychiatry, 2009, 32, 134-141.	0.9	140
35	Heroin overdose: the case for take-home naloxone. BMJ: British Medical Journal, 1996, 312, 1435-1436.	2.3	138
36	The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. International Review of Psychiatry, 2003, 15, 74-83.	2.8	132

#	Article	IF	CITATIONS
37	Drug use and initiation in prison: results from a national prison survey in England and Wales. Addiction, 2002, 97, 1551-1560.	3.3	131
38	Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. Addiction, 2017, 112, 1408-1418.	3.3	130
39	Psychosis in the Community and in Prisons: A Report From the British National Survey of Psychiatric Morbidity. American Journal of Psychiatry, 2005, 162, 774-780.	7.2	129
40	Crystalline methamphetamine use and methamphetamineâ€related harms in Australia. Drug and Alcohol Review, 2017, 36, 160-170.	2.1	126
41	Alpha ₂ -adrenergic agonists for the management of opioid withdrawal. The Cochrane Library, 2016, 2016, CD002024.	2.8	122
42	Psychosis and drug dependence: results from a national survey of prisoners. British Journal of Psychiatry, 2002, 181, 393-398.	2.8	120
43	Opiate withdrawal. Addiction, 1994, 89, 1471-1475.	3.3	117
44	Patterns of polydrug use in Great Britain: Findings from a national household population survey. Drug and Alcohol Dependence, 2011, 113, 222-228.	3.2	114
45	The relationship between personal debt and specific common mental disorders. European Journal of Public Health, 2013, 23, 108-113.	0.3	113
46	Psychiatric morbidity and substance use in young people aged 13–15 years: results from the Child and Adolescent Survey of Mental Health. British Journal of Psychiatry, 2003, 182, 509-517.	2.8	111
47	An evaluation of a brief motivational intervention among young ecstasy and cocaine users: no effect on substance and alcohol use outcomes. Addiction, 2006, 101, 1014-1026.	3.3	111
48	Is socioeconomic status in early life associated with drug use? A systematic review of the evidence. Drug and Alcohol Review, 2009, 28, 142-153.	2.1	110
49	Violence and Psychiatric Morbidity in a National Household Population-A Report from the British Household Survey. American Journal of Epidemiology, 2006, 164, 1199-1208.	3.4	109
50	Violence and psychiatric morbidity in the national household population of Britain: public health implications. British Journal of Psychiatry, 2006, 189, 12-19.	2.8	106
51	Trends in service use and treatment for mental disorders in adults throughout Great Britain. British Journal of Psychiatry, 2004, 185, 378-384.	2.8	104
52	Effectiveness of community treatments for heroin and crack cocaine addiction in England: a prospective, in-treatment cohort study. Lancet, The, 2009, 374, 1262-1270.	13.7	103
53	Stroke and methamphetamine use in young adults: a review. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1079-1091.	1.9	103
54	Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region. Addiction, 2002, 97, 771-772.	3.3	101

#	Article	IF	CITATIONS
55	Minimizing respondent attrition in longitudinal research: Practical implications from a cohort study of adolescent drinking. Journal of Adolescence, 2003, 26, 363-373.	2.4	99
56	Substitution treatment of injecting opioid users for prevention of HIV infection., 2008, , CD004145.		98
57	Lone mothers, social exclusion and depression. Psychological Medicine, 2003, 33, 715-722.	4.5	97
58	Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study. Drug and Alcohol Dependence, 2015, 147, 144-150.	3.2	97
59	Alcohol consumption as a risk factor for anxiety and depression. British Journal of Psychiatry, 2005, 187, 544-551.	2.8	94
60	Mental health outcomes associated with the use of amphetamines: A systematic review and meta-analysis. EClinicalMedicine, 2019, 16, 81-97.	7.1	91
61	Drug-Related Mortality and Fatal Overdose Risk: Pilot Cohort Study of Heroin Users Recruited From Specialist Drug Treatment Sites in London. Journal of Urban Health, 2003, 80, 274-287.	3.6	87
62	Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. Journal of General Internal Medicine, 2006, 21, 193-195.	2.6	83
63	Family Cohesion as a Buffer Against the Effects of Problem-Drinking Fathers on Psychological Distress, Deviant Behavior, and Heavy Drinking in Adolescents. Journal of Health and Social Behavior, 1995, 36, 377.	4.8	79
64	Route of drug use and its implications for drug effect, risk of dependence and health consequences. Drug and Alcohol Review, 1998, 17, 197-211.	2.1	78
65	The British Mental Health Survey Programme: achievements and latest findings. Social Psychiatry and Psychiatric Epidemiology, 2009, 44, 899-904.	3.1	78
66	Comorbidity of mental disorders with substance misuse. British Journal of Psychiatry, 1997, 171, 4-5.	2.8	75
67	The reluctance to seek treatment for neurotic disorders. International Review of Psychiatry, 2003, 15, 123-128.	2.8	74
68	Depression and common mental disorders in lone parents: results of the 2000 National Psychiatric Morbidity Survey. Psychological Medicine, 2008, 38, 335-342.	4. 5	74
69	Borderline personality disorder: health service use and social functioning among a national household population. Psychological Medicine, 2009, 39, 1721.	4.5	72
70	Obsessive-Compulsive Disorder: Prevalence, Comorbidity, Impact, and Help-Seeking in the British National Psychiatric Morbidity Survey of 2000. American Journal of Psychiatry, 2006, 163, 1978.	7.2	72
71	Socioâ€economic status in childhood and later alcohol use: a systematic review*. Addiction, 2007, 102, 1546-1563.	3.3	69
72	BRIEF REPORT: Methadone Treatment of Injecting Opioid Users for Prevention of HIV Infection. Journal of General Internal Medicine, 2006, 21, 193-195.	2.6	66

#	Article	IF	Citations
73	α ₂ â€Adrenergic agonists in opioid withdrawal. Addiction, 2002, 97, 49-58.	3.3	63
74	Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. Psychological Medicine, 2006, 36, 1441-1446.	4.5	63
75	The minimal number of TMS trials required for the reliable assessment of corticospinal excitability, short interval intracortical inhibition, and intracortical facilitation. Neuroscience Letters, 2018, 674, 94-100.	2.1	62
76	The National Psychiatric Morbidity Surveys of Great Britain-initial findings from the Household Survey. International Review of Psychiatry, 2003, 15, 29-42.	2.8	60
77	Trends in fentanyl prescriptions and fentanylâ€related mortality in <scp>A</scp> ustralia. Drug and Alcohol Review, 2013, 32, 269-275.	2.1	60
78	Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibility and 6-month outcome. Addiction, 2000, 95, 1631-1645.	3.3	56
79	Nicotine, alcohol and drug dependence, and psychiatric comorbidity-results of a national household survey. International Review of Psychiatry, 2003, 15, 50-56.	2.8	56
80	Effectiveness of drug dependence treatment in HIV prevention. International Journal of Drug Policy, 2005, 16, 67-75.	3.3	55
81	Estimating the prevalence of problem drug use in inner London: a discussion of three captureâ€recapture studies. Addiction, 1999, 94, 1653-1662.	3.3	54
82	Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study. BMJ Open, 2014, 4, e004666.	1.9	54
83	Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug and Alcohol Dependence, 2002, 67, 169-176.	3.2	53
84	Substance misuse among prisoners in England and Wales. International Review of Psychiatry, 2003, 15, 150-152.	2.8	53
85	Psychosocial treatment for opiate abuse and dependence. , 2004, , CD004330.		53
86	Obsessive–compulsive disorder and personality disorder. Social Psychiatry and Psychiatric Epidemiology, 2006, 41, 862-867.	3.1	53
87	Social support networks and type of neurotic symptom among adults in British households. Psychological Medicine, 2003, 33, 307-318.	4.5	50
88	Effect of Cytisine vs Varenicline on Smoking Cessation. JAMA - Journal of the American Medical Association, 2021, 326, 56.	7.4	50
89	Suicide and overdose among opiate addicts. Addiction, 1996, 91, 321-323.	3.3	50
90	Inâ€patient psychiatric care: The patient's view. The British Journal of Medical Psychology, 1989, 62, 249-255.	0.5	48

#	Article	IF	CITATIONS
91	Anticonvulsants for cocaine dependence. , 2008, , CD006754.		48
92	The treatment of common mental disorders across age groups: Results from the 2007 adult psychiatric morbidity survey. Journal of Affective Disorders, 2010, 127, 96-101.	4.1	48
93	Does prenatal exposure to influenza in mice induce pyramidal cell disarray in the dorsal hippocampus?. Schizophrenia Research, 1995, 16, 233-241.	2.0	46
94	Perceptions of extendedâ€release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. Addiction, 2020, 115, 1295-1305.	3.3	46
95	Risk factors and the prevalence of neurosis and psychosis in ethnic groups in Great Britain. Social Psychiatry and Psychiatric Epidemiology, 2004, 39, 939-946.	3.1	45
96	The Swiss heroin trials: testing alternative approaches. BMJ: British Medical Journal, 1998, 316, 639-639.	2.3	45
97	Alpha ₂ -adrenergic agonists for the management of opioid withdrawal., 2014, , CD002024.		44
98	Suicide and substance misuse. British Journal of Psychiatry, 1997, 171, 303-304.	2.8	43
99	Ethnic differences in prisoners. British Journal of Psychiatry, 2002, 181, 473-480.	2.8	43
100	Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients? Pain, 2016, 157, 1489-1498.	4.2	43
101	Benzodiazepinesin Polydrug-using Repertoires: the impact of the decreased availability of temazepam gel-filled capsules. Drugs: Education, Prevention and Policy, 1999, 6, 61-69.	1.3	42
102	Managing anxiety and depression in alcohol and drug dependence. Addictive Behaviors, 1998, 23, 919-931.	3.0	41
103	A systematic review and metaâ€analysis of naltrexone implants for the treatment of opioid dependence. Drug and Alcohol Review, 2014, 33, 115-128.	2.1	41
104	Treatment Seeking by Individuals With Obsessive-Compulsive Disorder From the British Psychiatric Morbidity Survey of 2000. Psychiatric Services, 2007, 58, 977-982.	2.0	40
105	Alpha2-adrenergic agonists for the management of opioid withdrawal., 2009,, CD002024.		39
106	Cohort protocol paper: The Pain and Opioids In Treatment (POINT) study. BMC Pharmacology & Emp; Toxicology, 2014, 15, 17.	2.4	39
107	Prevalence and Correlates of Suicidal Thoughts and Suicide Attempts in People Prescribed Pharmaceutical Opioids for Chronic Pain. Clinical Journal of Pain, 2016, 32, 292-301.	1.9	39
108	Use of nonâ€prescribed methadone and other illicit drugs during methadone maintenance treatment. Drug and Alcohol Review, 2000, 19, 9-16.	2.1	38

#	Article	IF	CITATIONS
109	The closure of the <scp>S</scp> ilk <scp>R</scp> oad: what has this meant for online drug trading?. Addiction, 2014, 109, 517-518.	3.3	38
110	Happiness across age groups: results from the 2007 National Psychiatric Morbidity Survey. International Journal of Geriatric Psychiatry, 2011, 26, 608-614.	2.7	37
111	Ethnic differences in prisoners. British Journal of Psychiatry, 2002, 181, 481-487.	2.8	36
112	Socio-economic status, standard of living, and neurotic disorder. International Review of Psychiatry, 2003, 15, 91-96.	2.8	36
113	The coâ€morbidity of personality disorder and clinical syndromes in prisoners. Criminal Behaviour and Mental Health, 2009, 19, 321-333.	0.8	36
114	Discrimination on the grounds of diagnosis. Addiction, 1990, 85, 883-890.	3.3	33
115	Methadone Treatment for Opiate Addiction: Benefits in the First Month. Addiction Research, 1997, 5, 71-76.	0.6	33
116	Alcohol consumption as a risk factor for non-recovery from common mental disorder: results from the longitudinal follow-up of the National Psychiatric Morbidity Survey. Psychological Medicine, 2008, 38, 451-455.	4.5	33
117	Mortality among people with regular or problematic use of amphetamines: a systematic review and metaâ€analysis. Addiction, 2019, 114, 1738-1750.	3.3	32
118	Psychiatric morbidity in prisoners and solitary cellular confinement, I: disciplinary segregation. Journal of Forensic Psychiatry and Psychology, 2003, 14, 298-319.	1.0	31
119	Factors associated with the development of depression in chronic non-cancer pain patients following the onset of opioid treatment for pain. Journal of Affective Disorders, 2015, 184, 72-80.	4.1	30
120	Pain sensitivity in Parkinson's disease: Systematic review and meta-analysis. Parkinsonism and Related Disorders, 2018, 48, 17-27.	2.2	30
121	Substance misuse and psychiatric comorbidity: an overview of the OPCS National Psychiatric Morbidity Survey. International Review of Psychiatry, 2003, 15, 43-49.	2.8	29
122	Personal and social correlates of alcohol consumption among midâ€adolescents. British Journal of Developmental Psychology, 2005, 23, 427-450.	1.7	29
123	The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. Drug and Alcohol Dependence, 2015, 151, 56-67.	3.2	29
124	Which medications are suitable for agonist drug maintenance?. Addiction, 2016, 111, 767-774.	3.3	28
125	The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. Lancet Psychiatry,the, 2018, 5, 155-166.	7.4	28
126	The effectiveness and cost-effectiveness of diversion and aftercare programmes for offenders using class A drugs: a systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-168.	2.8	28

#	Article	IF	CITATIONS
127	The relative impact of waiting time and treatment entry on drug and alcohol use. Addiction Biology, 2002, 7, 67-74.	2.6	26
128	Unequal access and unmet need: neurotic disorders and the use of primary care services. International Review of Psychiatry, 2003, 15, 115-122.	2.8	26
129	Cochrane systematic reviews in the field of addiction: What's there and what should be. Drug and Alcohol Dependence, 2011, 113, 96-103.	3.2	26
130	Yes, people can die from opiate withdrawal. Addiction, 2017, 112, 199-200.	3.3	26
131	Neurotic disorders and the receipt of psychiatric treatment. International Review of Psychiatry, 2003, 15, 108-114.	2.8	25
132	Screening for hepatitis B and vaccination of injecting drug users in NHS drug treatment services. Addiction, 1990, 85, 1657-1659.	3.3	23
133	Fatal opioid overdoses during and shortly after hospital admissions in England: A case-crossover study. PLoS Medicine, 2021, 18, e1003759.	8.4	23
134	Clinical Features of Patients Attending a Gender-Identity Clinic. British Journal of Psychiatry, 1990, 157, 265-268.	2.8	22
135	The National Survey of Psychiatric Morbidity among Prisoners and the Future of Prison Healthcare. Medicine, Science and the Law, 2002, 42, 245-250.	1.0	22
136	A systematic review of modelling approaches in economic evaluations of health interventions for drug and alcohol problems. BMC Health Services Research, 2016, 16, 127.	2.2	22
137	Predictors of retention in a randomised trial of smoking cessation in low-socioeconomic status Australian smokers. Addictive Behaviors, 2017, 64, 13-20.	3.0	22
138	Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. International Journal of Drug Policy, 2022, 100, 103492.	3.3	22
139	Minimising the misuse of oxycodone and other pharmaceutical opioids in Australia. Medical Journal of Australia, 2011, 195, 248-249.	1.7	21
140	Would legalizing illicit opioids reduce overdose fatalities? Implications from a natural experiment. Addiction, 2014, 109, 1237-1242.	3.3	21
141	<i>The lesser of two evils</i> ': A qualitative study of staff and client experiences and beliefs about addressing tobacco in addiction treatment settings. Drug and Alcohol Review, 2016, 35, 92-101.	2.1	20
142	Parkinson disease: A systemic review of pain sensitivities and its association with clinical pain and response to dopaminergic stimulation. Journal of the Neurological Sciences, 2018, 395, 172-206.	0.6	20
143	Evaluating the potential impact of a reformulated version of oxycodone upon tampering, nonâ€adherence and diversion of opioids: the <scp>N</scp> ational <scp>O</scp> pioid <scp>M</scp> edications <scp>A</scp> buse <scp>D</scp> eterrence (<scp>NOMAD</scp>) study protocol. Addiction. 2015. 110. 226-237.	3.3	19
144	Characteristics and circumstances of death related to new psychoactive stimulants and hallucinogens in Australia. Drug and Alcohol Dependence, 2019, 204, 107556.	3.2	19

#	Article	IF	CITATIONS
145	Alpha2 adrenergic agonists for the management of opioid withdrawal., 2004,, CD002024.		18
146	Maintenance drugs to treat opioid dependence. BMJ, The, 2012, 344, e2823-e2823.	6.0	18
147	Excess mortality among opioidâ€using patients treated with oral naltrexone in <scp>A</scp> ustralia. Drug and Alcohol Review, 2015, 34, 90-96.	2.1	18
148	Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot. International Journal of Drug Policy, 2022, 107, 103788.	3.3	18
149	Substance Use and Misuse in Childhood and Adolescence. Journal of Child Psychology and Psychiatry and Allied Disciplines, 1991, 32, 109-128.	5.2	17
150	Reducing Drug Related Deaths By The Advisory Council on the Misuse of Drugs. London: Stationery Office. 2000. 123 pp. £11.50. ISBN: 0-11-341-239-8 Psychiatric Bulletin, 2002, 26, 119-119.	0.3	17
151	Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study. EClinicalMedicine, 2020, 28, 100592.	7.1	16
152	Prescription of diamorphine, dipipanone and cocaine in England and Wales. Drug and Alcohol Review, 1997, 16, 221-226.	2.1	15
153	Psychiatric morbidity in prisoners and solitary cellular confinement, II: special ('strip') cells. Journal of Forensic Psychiatry and Psychology, 2003, 14, 320-340.	1.0	15
154	Opioid maintenance in European prisons: is the treatment gap closing?. Addiction, 2012, 107, 461-463.	3.3	15
155	Should doctors prescribe cannabinoids?. BMJ, The, 2014, 348, g2737-g2737.	6.0	15
156	Compulsory treatment of addiction in the patient's best interests: More rigorous evaluations are essential. Drug and Alcohol Review, 2014, 33, 268-271.	2.1	15
157	Estimated verbal IQ and the odds of problem gambling: a population-based study. Psychological Medicine, 2014, 44, 1739-1749.	4.5	15
158	Heroin-assisted treatment: has a controversial treatment come of age?. British Journal of Psychiatry, 2015, 207, 3-4.	2.8	15
159	Trends in new psychoactive substances from surface and "dark―net monitoring. Lancet Psychiatry,the, 2017, 4, 16-18.	7.4	15
160	Strategies to reduce drug-related harm: responding to the evidence base. Lancet, The, 2019, 394, 1490-1493.	13.7	15
161	The contribution of methamphetamine use to crime: Evidence from Australian longitudinal data. Drug and Alcohol Dependence, 2020, 216, 108262.	3.2	15
162	Trends in cocaine use, markets and harms in Australia, 2003–2019. Drug and Alcohol Review, 2021, 40, 946-956.	2.1	15

#	Article	IF	CITATIONS
163	Client Perceptions of Inpatient Treatment: a qualitative account with implications for service delivery. Drugs: Education, Prevention and Policy, 1999, 6, 87-97.	1.3	14
164	British Psychiatric Morbidity Survey. International Review of Psychiatry, 2003, 15, 14-18.	2.8	14
165	Integrating HIV preâ€exposure prophylaxis and harm reduction among men who have sex with men and transgender women to address intersecting harms associated with stimulant use: a modelling study. Journal of the International AIDS Society, 2020, 23, e25495.	3.0	14
166	Cocaine in Britain: Prevalence, Problems, and Treatment Responses. Journal of Drug Issues, 1998, 28, 225-241.	1.2	13
167	The National Psychiatric Morbidity Surveys of Great Britain-strategy and methods. International Review of Psychiatry, 2003, 15, 5-13.	2.8	13
168	Predictors of Mental Health Service Utilization in the 12 Months before Imprisonment: Analysis of Results from a National Prisons Survey. Australian and New Zealand Journal of Psychiatry, 2006, 40, 548-553.	2.3	13
169	A randomized clinical trial of a financial education intervention with nicotine replacement therapy (<scp>NRT</scp>) for low socioâ€economic status <scp>A</scp> ustralian smokers: a study protocol. Addiction, 2014, 109, 1602-1611.	3.3	13
170	Cannabis dependence and withdrawal. Addiction, 1999, 94, 1277-1278.	3.3	12
171	Drugs: Dilemmas and Choices By a Working Party of the Royal College of Psychiatrists and the Royal College of Physicians. London: Gaskell. 2000. 304 pp. £9.50 (pb). ISBN 1 901242 447. British Journal of Psychiatry, 2001, 178, 484-484.	2.8	12
172	Antidepressant Use Among People Prescribed Opioids for Chronic Noncancer Pain. Pain Medicine, 2019, 20, 2450-2458.	1.9	12
173	The impact of opioid agonist treatment on hospitalisations for injecting-related diseases among an opioid dependent population: A retrospective data linkage study. Drug and Alcohol Dependence, 2022, 236, 109494.	3.2	12
174	Britain's new strategy for tackling drugs misuse. BMJ: British Medical Journal, 1998, 316, 1399-1400.	2.3	11
175	Postâ€marketing studies of pharmaceutical opioid abuseâ€deterrent formulations: a framework for research design and reporting. Addiction, 2019, 114, 389-399.	3.3	11
176	The effectiveness, safety and costâ€effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled nonâ€inferiority trial. Addiction, 2019, 114, 923-933.	3.3	11
177	Prevalence and Characteristics Associated with Chronic Noncancer Pain in Suicide Decedents: A National Study. Suicide and Life-Threatening Behavior, 2020, 50, 778-791.	1.9	11
178	Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions. International Journal of Drug Policy, 2022, 99, 103472.	3.3	11
179	Modeling the populationâ€level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia. Addiction, 2022, 117, 1338-1352.	3.3	11
180	Trends in comorbid opioid and stimulant use disorders among Veterans receiving care from the Veterans Health Administration, 2005–2019. Drug and Alcohol Dependence, 2022, 232, 109310.	3.2	11

#	Article	IF	Citations
181	Time of day of methadone consumption and illicit heroin use. Drug and Alcohol Dependence, 1997, 49, 49-54.	3.2	10
182	HIV in injecting drug users in Asian countries. BMJ: British Medical Journal, 2004, 329, 697-698.	2.3	10
183	Substance use and psychiatric comorbidity. Medicine, 2007, 35, 246-249.	0.4	10
184	Hepatitis B vaccination in prisons: a muchâ€needed targeted universal intervention. Addiction, 2010, 105, 189-190.	3.3	10
185	Job Strain, Hazardous Drinking, and Alcohol-Related Disorders Among Brazilian Bank Workers. Journal of Studies on Alcohol and Drugs, 2013, 74, 212-222.	1.0	10
186	An organisational change intervention for increasing the delivery of smoking cessation support in addiction treatment centres: study protocol for a randomized controlled trial. Trials, 2016, 17, 290.	1.6	10
187	Coping with problematic drug use in the family: An evaluation of the <scp>S</scp> tepping <scp>S</scp> tones program. Drug and Alcohol Review, 2016, 35, 470-476.	2.1	10
188	Crossover design in transcranial direct current stimulation studies on motor learning: potential pitfalls and difficulties in interpretation of findings. Reviews in the Neurosciences, 2018, 29, 463-473.	2.9	10
189	Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001–2018: Implications for treatment systems and potential impact on client outcomes. Drug and Alcohol Dependence, 2021, 219, 108464.	3.2	10
190	Patterns of smoking and injecting methamphetamine and their association with health and social outcomes. Drug and Alcohol Review, 2021, 40, 1256-1265.	2.1	10
191	Opioid Substitution: Critical Issues and Future Directions. Journal of Drug Issues, 1998, 28, 243-263.	1.2	10
192	Compressed opiate withdrawal syndrome and naltrexone. Journal of Psychopharmacology, 1995, 9, 383-385.	4.0	9
193	Organization and delivery of treatment services for dual diagnosis. Psychiatry (Abingdon, England), 2007, 6, 34-36.	0.2	9
194	Excessive gambling and gaming: addictive disorders?. Lancet Psychiatry,the, 2017, 4, 433-435.	7.4	9
195	Effect of increasing the delivery of smoking cessation care in alcohol and other drug treatment centres: a clusterâ€randomized controlled trial. Addiction, 2020, 115, 1345-1355.	3.3	9
196	Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study. BMJ Open, 2020, 10, e034389.	1.9	9
197	Characteristics and circumstances of death related to the selfâ€administration of ketamine. Addiction, 2021, 116, 339-345.	3.3	9
198	Assessing the concurrent validity, interâ€rater reliability and test–reâ€test reliability of the Australian Treatment Outcomes Profile (ATOP) in alcohol and opioid treatment populations. Addiction, 2021, 116, 1245-1255.	3.3	9

#	Article	IF	Citations
199	Clinical correlates and outcomes associated with pregabalin use among people prescribed opioids for chronic nonâ€cancer pain: A fiveâ€year prospective cohort study. British Journal of Clinical Pharmacology, 2021, 87, 3092-3104.	2.4	9
200	Beyond Platitudes: Problem Drug Use: a review of training. Addiction, 1990, 85, 1559-1562.	3.3	8
201	Patients' preferences and randomised trials. Lancet, The, 1994, 344, 688-689.	13.7	8
202	Cannabis and health. British Journal of Psychiatry, 2001, 178, 98-98.	2.8	8
203	Development of a Brief Patient-Administered Screening Tool for Prescription Opioid Dependence for Primary Care Settings. Pain Medicine, 2020, 21, e79-e88.	1.9	8
204	Trajectories of alcoholâ€induced blackouts in adolescence: early risk factors and alcohol use disorder outcomes in early adulthood. Addiction, 2021, 116, 2039-2048.	3.3	8
205	Ecstasy and the Oxygen of Publicity. Addiction, 1989, 84, 943-943.	3.3	7
206	The use of paracetamol (acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids. International Journal of Clinical Practice, 2015, 69, 1366-1376.	1.7	7
207	Factors associated with Quitline and pharmacotherapy utilisation among low-socioeconomic status smokers. Addictive Behaviors, 2019, 89, 113-120.	3.0	7
208	Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a crossâ€sectional survey of Australian treatment clients. Drug and Alcohol Review, 2022, 41, 841-850.	2.1	7
209	Dying for heroin: the increasing opioid-related mortality in the Republic of Ireland, 1980–1999. European Journal of Public Health, 2005, 15, 589-592.	0.3	6
210	Substance use and psychosis. Psychiatry (Abingdon, England), 2007, 6, 19-22.	0.2	6
211	Circumstances of death of opioid users being treated with naltrexone. Addiction, 2019, 114, 2000-2007.	3.3	6
212	Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms – An fMRI study. Journal of the Neurological Sciences, 2020, 416, 116905.	0.6	6
213	The Technology of Dragon Chasing. Addiction, 1989, 84, 699-699.	3.3	5
214	Substance use and psychosis. Psychiatry (Abingdon, England), 2004, 3, 52-54.	0.2	5
215	Psychosocial treatment for opiate abuse and dependence. The Cochrane Library, 2014, , CD004330.	2.8	5
216	Drinking-reduction goals offer potential to widen the options for measuring and treating alcohol dependence. Lancet Psychiatry,the, 2017, 4, 430-431.	7.4	5

#	Article	IF	Citations
217	Characteristics of fatal gabapentinoid-related poisoning in Australia, 2000–2020. Clinical Toxicology, 2022, 60, 304-310.	1.9	5
218	Directly observed treatment for tuberculosis. BMJ: British Medical Journal, 1996, 313, 45-45.	2.3	5
219	CLASSIFICATION AND CONFUSION. Addiction, 2010, 105, 1150-1150.	3.3	4
220	Smoking and finances: baseline characteristics of low income daily smokers in the FISCALS cohort. International Journal for Equity in Health, 2017, 16, 157.	3.5	4
221	Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018. JAMA Network Open, 2021, 4, e213059.	5.9	4
222	Determining clinical cutoff scores for the Australian Treatment Outcomes Profile psychological health, physical health and quality of life questions. Drug and Alcohol Review, 2021, , .	2.1	4
223	The lure of masterstrokes: drug legalization. Addiction, 1990, 85, 5-7.	3.3	3
224	Pharmaceutical heroin and 'chasing the dragon' From Malcolm Battersby, Michael Farrell & John Strong. Addiction, 1990, 85, 151-151.	3.3	3
225	Substance use and psychiatric comorbidity. Psychiatry (Abingdon, England), 2004, 3, 55-58.	0.2	3
226	Variation in mortality risk of people released from prison. Lancet Psychiatry, the, 2015, 2, 681.	7.4	3
227	Reducing extramedical use and harms of pharmaceutical opioids: the potential role of abuse-deterrent formulations. Lancet Psychiatry,the, 2015, 2, 957-959.	7.4	3
228	Who would try (or use more) cannabis if it were legal?. Drug and Alcohol Review, 2021, , .	2.1	3
229	Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a crossâ€sectional study in three Australian cities. Addiction, 2021, 116, 1482-1494.	3.3	3
230	Confusion between the drug legalization and the drug prescribing debate. Drug and Alcohol Review, 1990, 9, 364-368.	2.1	2
231	Substance misusers attending a psychiatric emergency clinic. Journal of Mental Health, 1992, 1, 163-168.	1.9	2
232	Organization and delivery of treatment services for dual diagnosis. Psychiatry (Abingdon, England), 2004, 3, 62-64.	0.2	2
233	Predictors of mental health service utilization in the 12i;½months before imprisonment: analysis of results from a national prisons survey. Australian and New Zealand Journal of Psychiatry, 2006, 40, 548-553.	2.3	2
234	Commentary on <scp>K</scp> elty & Description of the comparison of mortality between patients prescribed implanted or oral naltrexone an unbiased and unconfounded comparison?. Addiction, 2012, 107, 1825-1826.	3.3	2

#	Article	IF	Citations
235	Drug legalisation. BMJ, The, 2014, 349, g5233-g5233.	6.0	2
236	Commentary on Singh <i>et al</i> . (2016): Still searching for the answer. Addiction, 2016, 111, 1347-1347.	3.3	2
237	Effectiveness and framing of pharmaceutical opioid abuseâ€deterrent formulations. Addiction, 2019, 114, 404-405.	3.3	2
238	What can we learn from the history of research on psychedelic drugs in the addictions?. Addiction, 2021, 116, 2936-2938.	3.3	2
239	Methadone maintenance treatment. BMJ: British Medical Journal, 1995, 310, 1408-1408.	2.3	2
240	Characteristics of fatal tapentadolâ€related toxicity in Australia. Drug and Alcohol Review, 2022, , .	2.1	2
241	New models of services for drug misusers. Psychiatric Bulletin, 1989, 13, 645-647.	0.3	1
242	Review: family or couples therapy is more effective than non-family therapy for drug abuse. Evidence-Based Mental Health, 1998, 1, 81-81.	4.5	1
243	A programme of methadone maintenance plus moderate counselling services was cost effective. Evidence-Based Mental Health, 1998, 1, 63-63.	4.5	1
244	Epidemiology of tobacco, alcohol and drug use. Psychiatry (Abingdon, England), 2006, 5, 427-430.	0.2	1
245	Substance use and psychiatric comorbidity. Psychiatry (Abingdon, England), 2007, 6, 23-26.	0.2	1
246	Drug use and drug dependence., 0,, 230-249.		1
247	Motivational Interviewing in the Treatment of Psychological Problems Edited by Hal Arkowitz, Henny A. Westra, William R. Miller & Stephen Rollnick. Guilford. 2007. US\$38.00 (hb). 354pp. ISBN: 9781593855857. British Journal of Psychiatry, 2009, 194, 471-471.	2.8	1
248	Community treatments for heroin and crack cocaine addiction – Authors' reply. Lancet, The, 2010, 375, 278-279.	13.7	1
249	Commentary on Agrawal et $\hat{a} \in f$ al. (2011): Assessing the impact of changes to diagnostic criteria on the estimated prevalence of alcohol use disorders in general population surveys. Addiction, 2011, 106, 1944-1945.	3.3	1
250	Response to commentaries on †Which medications are suitable for agonist drug maintenance'. Addiction, 2016, 111, 781-782.	3.3	1
251	Cannabis use and non-cancer chronic pain – Authors' reply. Lancet Public Health, The, 2018, 3, e469.	10.0	1
252	Prisoners and risk of injury after release. Lancet Public Health, The, 2018, 3, e209-e210.	10.0	1

#	Article	IF	Citations
253	The Lower-Risk Cannabis Use Guidelines (LRCUG): A ready-made targeted prevention tool for cannabis in New Zealand. Public Health in Practice, 2020, 1, 100046.	1.5	1
254	When the evidence is not enough: is it time to rethink trial design?. Addiction, 2021, 116, 711-712.	3.3	1
255	Aldous Huxley's Doors of Perception. Addiction, 2021, , .	3.3	1
256	Young People and Alcohol. Addiction, 1988, 83, 1137-1138.	3.3	0
257	Relapse Prevention for Addictive Behaviours: A Manual for Therapists. By Shamil Wanigaratne, Wendy Wallace, Jane Pullin, Francis Keaney and Roger Farmer. Oxford: Blackwell Scientific Publications. 1990. 205 pp. £12.95 British Journal of Psychiatry, 1991, 158, 875-875.	2.8	O
258	Cocaine: Physiological and Physiopathological Effects. Edited by Alfonso Paredes and David A. Gorelick. New York: Haworth. 1992. 130 pp. US \$26.95 (hb) or \$23.95 (pb) British Journal of Psychiatry, 1994, 165, 708-709.	2.8	0
259	Methadone-maintenance and the prognosis paradox. Addiction, 1994, 89, 812-813.	3.3	O
260	Young People and Substance Misuse. Child and Adolescent Mental Health, 2006, 11, 61-61.	3.5	0
261	Review: Substance use disorders respond to psychosocial interventions. Evidence-Based Mental Health, 2008, 11, 123-123.	4.5	O
262	Griffith Edwards, the Addiction Research Unit and research on the criminal justice system. Addiction, 2015, 110, 54-58.	3.3	0
263	Demons: Our Changing Attitudes to Alcohol, Tobacco, and Drugs edited by VirginiaBerridge (Ed) Oxford, UK: Oxford University Press, 2013ISBN: 978 0 19 960498 2, 292 pp. Hardback. Price: Â Alcohol Review, 2015, 34, 231-231.	£ 1.6 .99. Dı	rwog and
264	Opioid agonist maintenance for opioid dependent patients in prison. The Cochrane Library, 0, , .	2.8	0
265	Commentary on Binswanger <i>et al</i> . (2016): Multiple opportunities exist to improve the health and wellbeing of people released from prisons. Addiction, 2016, 111, 511-512.	3.3	O
266	Swift and certain approaches to reduce alcohol reoffending. Lancet Psychiatry, the, 2016, 3, 189-190.	7.4	0
267	Commentary on McDonald <i>et al</i> . (2018): Intranasal naloxoneâ€"from the laboratory to the real world. Addiction, 2018, 113, 494-495.	3.3	O
268	Burroughs' â€~Letter from a master addict to dangerous drugs': a forgotten classic. Addiction, 2018, 113, 2305-2308.	3.3	0
269	Commentary on Hoet al. (2020): Managing people with HIV and drug problems is complex and multiâ€faceted. Addiction, 2020, 115, 653-654.	3.3	O
270	Advanced Summer School in Addictions. Psychiatric Bulletin, 1990, 14, 39-40.	0.3	0

#	Article	IF	CITATIONS
271	Cocaine: Physiological and Physiopathological Effects. Edited by Alfonso Paredes and David A. Gorelick. New York: Haworth. 1992. 130 pp. US \$26.95 (hb) or \$23.95 (pb) British Journal of Psychiatry, 1994, 165, 708-709.	2.8	O
272	Prescription charges. Bulletin of the Royal College of Psychiatrists, 1987, 11, 102-102.	0.0	0